MetaCap

MiMedx Group Inc (MDXG)

NASDAQ: MDXGHealth CareMedical/Dental InstrumentsUSD

3.05-0.06 (-1.93%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MDXG stock chart

Technical analysis

Key statistics

All statistics
Market cap
$445.07M
EPS (TTM)
-$0.13
52-week range
3.03 – 7.45
Day range
3.03 – 3.14
Volume / Avg
2.12M / 1.39M
Beta
—

52-week range

$3.03$7.45

MDXG stock today

On Nov 20, MDXG ended the session at $3.05, shedding $0.06 (1.93%), versus the S&P 500's 3.70% decline. At this level, MDXG sits near the bottom of its 52-week range of $3.03 to $7.45: 59.1% below the high, set on Dec 18, 2025 and 0.7% above the low. MDXG is down 54.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 54.9%.

MiMedx Group has posted a net loss over the last twelve months (EPS of -$0.13), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About MiMedx Group

Company profile

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors.

Industry
Medical/Dental Instruments
CEO
Mr. Joseph H. Capper
Headquarters
Marietta, GA
Employees
808
Website
mimedx.com

Financial highlights

Full financials

In fiscal 2025, MiMedx Group generated $418.6 million in revenue, up 20.0% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $48.6 million (+14.5% year over year), for a net margin of 11.6% versus a median of -4.2% in the prior 5 years. Gross margin was 82.6% (down from 82.8%) and operating margin 15.3%.

MiMedx Group annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$418.63M$348.88M$321.48M$267.84M$242.02M
Growth+19.99%+8.52%+20.03%+10.67%-2.50%
Net income$48.58M$42.42M$58.23M$-30.20M$-10.29M
EPS (diluted)$0.32$0.28$0.37$-0.33$-0.15

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$7.00+129.51%

  • Strong buy 1
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $6.00High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 28, 2026
EPS actual vs est.
$-0.06 vs —

MDXG news

All MDXG news

MiMedx Group peers

Health Care sector
MDXG peer companies
CompanyPrice% ChgMarket capCompare
ANGOAngioDynamics Inc.10.81+0.46%$454.61Mvs MDXG
SENSSenseonics Holdings Inc.8.02-9.94%$439.34Mvs MDXG
CARLCarlsmed Inc.17.42+1.16%$477.38Mvs MDXG
SIShoulder Innovations Inc.20.15-0.79%$421.58Mvs MDXG
RCELAvita Medical Inc.15.62-2.31%$494.96Mvs MDXG
MOBIMobia Medical Inc.11.85-0.08%$394.50Mvs MDXG
CERSCerus Corporation1.85-2.63%$373.62Mvs MDXG
SGHTSight Sciences Inc.10.18-4.14%$565.79Mvs MDXG

Indexes, lists and sector

MiMedx Group stock FAQ

What is MiMedx Group's stock price today?

MDXG last traded at $3.05 as of Nov 20, 4:00 PM EST, down 1.93% on the day. Prices are delayed at least 15 minutes.

Does MiMedx Group pay a dividend?

No. MiMedx Group does not currently pay a regular cash dividend.

Who is MiMedx Group's CEO?

Mr. Joseph H. Capper is the chief executive officer of MiMedx Group Inc, which has about 808 employees.

Has MDXG ever split its stock?

Yes. The most recent MDXG stock split was a 3235-for-10000 split on Apr 2, 2008.

What is the MDXG 52-week high?

The 52-week high for MDXG is $7.45 and the 52-week low is $3.03. The stock is currently 59.1% below its high.

Compare MDXG